The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Related Posts
How much holiday cheer is too much? Investor enthusiasm on stocks running high into year-end
Michael Santoli breaks down the jump in investor spirits that’s caused them to run for riskier assets and stocks like bitcoin and MicroStrategy.
‘Go for gold’ says Goldman Sachs, but other Wall Street banks aren’t so sure
JPMorgan prefers other assets that offer annual yields. UBS, meanwhile, says gold price growth is likely to slow.
Elon Musk’s xAI Holdings in talks to raise $20 billion, Bloomberg News reports
The funding would value the company at over $120 billion, according to the Bloomberg report.